Circadian clock-controlled regulation of cGMP-protein kinase G in the nocturnal domain.
The suprachiasmatic nucleus (SCN) circadian clock exhibits a recurrent series of dynamic cellular states, characterized by the ability of exogenous signals to activate defined kinases that alter clock time. To explore potential relationships between kinase activation by exogenous signals and endogenous control mechanisms, we examined clock-controlled protein kinase G (PKG) regulation in the mammalian SCN. Signaling via the cGMP-PKG pathway is required for light- or glutamate (GLU)-induced phase advance in late night. Spontaneous cGMP-PKG activation occurred at the end of subjective night in free-running SCN in vitro. Phasing of the SCN rhythm in vitro was delayed by approximately 3 hr after treatment with guanylyl cyclase (GC) inhibitors, PKG inhibition, or antisense oligodeoxynucleotide (alphaODN) specific for PKG, but not PKA inhibitor or mismatched ODN. This sensitivity to GC-PKG inhibition was limited to the same 2 hr time window demarcated by clock-controlled activation of cGMP-PKG. Inhibition of the cGMP-PKG pathway at this time caused delays in the phasing of four endogenous rhythms: wheel-running activity, neuronal activity, cGMP, and Per1. Timing of the cGMP-PKG-necessary window in both rat and mouse depended on clock phase, established by the antecedent light/dark cycle rather than solar time. Because behavioral, neurophysiological, biochemical, and molecular rhythms showed the same temporal sensitivities and qualitative responses, we predict that clock-regulated GC-cGMP-PKG activation may provide a necessary cue as to clock state at the end of the nocturnal domain. Because sensitivity to phase advance by light-GLU-activated GC-cGMP-PKG occurs in juxtaposition, these signals may induce a premature shift to this PKG-necessary clock state.
Tischkau
Shelley A
SA
Department of Cell and Structural Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 60801, USA.
Weber
E Todd
ET
Abbott
Sabra M
SM
Mitchell
Jennifer W
JW
Gillette
Martha U
MU
D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal; D002227:Carbazoles; D018797:Cell Cycle Proteins; D002478:Cells, Cultured; D002940:Circadian Rhythm; D006152:Cyclic GMP / Q000378:metabolism; D017869:Cyclic GMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D003624:Darkness; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007211:Indoles; D007700:Kinetics; D009474:Neurons / Q000187:drug effects / Q000201:enzymology / Q000502:physiology; D009687:Nuclear Proteins / Q000378:metabolism; D020319:Oligodeoxyribonucleotides, Antisense / Q000235:genetics; D056950:Period Circadian Proteins; D051381:Rats; D012420:Running; D013493:Suprachiasmatic Nucleus / Q000201:enzymology* / Q000502:physiology*
D000470:Alkaloids; D002227:Carbazoles; D018797:Cell Cycle Proteins; D004791:Enzyme Inhibitors; D007211:Indoles; D009687:Nuclear Proteins; D020319:Oligodeoxyribonucleotides, Antisense; C539023:Per1 protein, mouse; C539024:Per1 protein, rat; D056950:Period Circadian Proteins; C073601:KT 5823; D017869:Cyclic GMP-Dependent Protein Kinases; D006152:Cyclic GMP